The RNA-unwinding activity of hepatitis C virus non-structural protein 3 (NS3) is positively modulated by its protease domain

被引:6
|
作者
Gu, BH
Pruss, CM
Gates, AT
Khandekar, SS
机构
[1] GlaxoSmityKline, GEPB, King Of Prussia, PA 19406 USA
[2] GlaxoSmithKline, Dept Mol Virol, Metab & Viral Dis Ctr Excellence Drug Discovery, Collegeville, PA 19426 USA
来源
PROTEIN AND PEPTIDE LETTERS | 2005年 / 12卷 / 04期
关键词
HCV; NS3; protease domain; helicase domain; E; coli; baculovirus; unwinding activity;
D O I
10.2174/0929866053765716
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The nonstructural protein 3 (NS3) of hepatitis C virus contains a protease domain at its amino terminus and RNA helicase domain at its carboxyl terminus. To identify optimal NS3 protein for developing screening assays, we expressed full-length NS3 protease/helicase and helicase domains from both HCV type 1a (H77 strain) and 1b (Con1 strain), using either E. coli or baculovirus expression systems. Our studies showed that the full-length NS3 proteins, either with or without the presence of the NS4A domain, from either strains were at least 10-fold more efficient than the corresponding helicase domains in unwinding partial duplex RNA substrates. These findings provide a rationale for the use of full-length NS3 in high throughput screening assays to identify potent small molecule inhibitors of this important target of HCV.
引用
收藏
页码:315 / 321
页数:7
相关论文
共 50 条
  • [21] NS3 Protease from Hepatitis C Virus: Biophysical Studies on an Intrinsically Disordered Protein Domain
    Vega, Sonia
    Neira, Jose L.
    Marcuello, Carlos
    Lostao, Anabel
    Abian, Olga
    Velazquez-Campoy, Adrian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (07): : 13282 - 13306
  • [22] Activity of purified hepatitis C virus protease NS3 on peptide substrates
    Steinkuhler, C
    Urbani, A
    Tomei, L
    Biasiol, G
    Sardana, M
    Bianchi, E
    Pessi, A
    DeFrancesco, R
    JOURNAL OF VIROLOGY, 1996, 70 (10) : 6694 - 6700
  • [23] Potent novel inhibitors against hepatitis C virus NS3 (HCV NS3 GT-3a) protease domain
    Ikram, Saima
    Ahmad, Jamshaid
    Rehman, Irshad-Ur
    Durdagi, Serdar
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2020, 101
  • [24] Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor
    de Bruijne, J.
    Thomas, X. V.
    Rebers, S. P.
    Weegink, C. J.
    Treitel, M. A.
    Hughes, E.
    Bergmann, J. F.
    de Knegt, R. J.
    Janssen, H. L. A.
    Reesink, H. W.
    Molenkamp, R.
    Schinkel, J.
    JOURNAL OF VIRAL HEPATITIS, 2013, 20 (11) : 779 - 789
  • [25] The RNA aptamer-binding site of hepatitis C virus NS3 protease
    Hwang, J
    Fauzi, H
    Fukuda, K
    Sekiya, S
    Kakiuchi, N
    Shimotohno, K
    Taira, K
    Kusakabe, I
    Nishikawa, S
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 279 (02) : 557 - 562
  • [26] Hepatitis C virus NS3/4A protease
    Kwong, AD
    Kim, JL
    Rao, G
    Lipovsek, D
    Raybuck, SA
    ANTIVIRAL RESEARCH, 1998, 40 (1-2) : 1 - 18
  • [27] Hepatitis C virus NS3/4A protease
    Kwong, AD
    CURRENT OPINION IN INFECTIOUS DISEASES, 1997, 10 (06) : 485 - 490
  • [28] An RNA ligand inhibits hepatitis C virus NS3 protease and helicase activities
    Fukuda, K
    Umehara, T
    Sekiya, S
    Kunio, K
    Hasegawa, T
    Nishikawa, S
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 325 (03) : 670 - 675
  • [30] Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus
    Urvil, PT
    Kakiuchi, N
    Zhou, DM
    Shimotohno, K
    Kumar, PKR
    Nishikawa, S
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 248 (01): : 130 - 138